Close

Scynexis (SCYX) Announces Receipt of FDA Orphan Drug Designation for SCY-078 as Aspergillus Infections Treatment

August 24, 2016 9:06 AM EDT Send to a Friend
Drug development company SCYNEXIS, Inc. (Nasdaq: SCYX) announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login